document.write("
"); document.write("
Burström,\ K.*\ ; Teni,\ F.S.*\ ; Gerdtham,\ U.G.*\ ; Leidl,\ R.\ ; Helgesson,\ G.*\ ; Rolfson,\ O.*\ ; Henriksson,\ M.*
"); document.write("
Experience-based Swedish TTO and VAS value sets for EQ-5D-5L health states.
"); document.write("
Pharmacoeconomics 38, 839-856 (2020)
"); document.write("
"); document.write("
"); document.write("
Kähm,\ K.\ ; Laxy,\ M.\ ; Schneider,\ U.*\ ; Holle,\ R.
"); document.write("
Exploring different strategies of assessing the economic impact of multiple diabetes-associated complications and their interactions: A large claims-based in Germany.
"); document.write("
Pharmacoeconomics 37, 63-74 (2019)
"); document.write("
"); document.write("
"); document.write("
Laxy,\ M.\ ; Schöning,\ V.M.\ ; Kurz,\ C.F.\ ; Holle,\ R.\ ; Peters,\ A.\ ; Meisinger,\ C.\ ; Rathmann,\ W.*\ ; Mühlenbruch,\ K.*\ ; Kähm,\ K.
"); document.write("
Performance of the UKPDS outcomes model 2 for predicting death and cardiovascular events in patients with type 2 diabetes mellitus from a German Population-Based Cohort.
"); document.write("
Pharmacoeconomics 37, 1485-1494 (2019)
"); document.write("
"); document.write("
"); document.write("
Stollenwerk,\ B.\ ; Iannazzo,\ S.*\ ; Akehurst,\ R.*\ ; Adena,\ M.*\ ; Briggs,\ A.*\ ; Dehmel,\ B.*\ ; Parfrey,\ P.*\ ; Belozeroff,\ V.*
"); document.write("
A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet.
"); document.write("
Pharmacoeconomics 36, 603-612 (2018)
"); document.write("
"); document.write("
"); document.write("
Iglesias,\ C.P.*\ ; Thompson,\ A.*\ ; Rogowski,\ W.H.\ ; Payne,\ K.*
"); document.write("
Reporting guidelines for the use of expert judgement in model-based economic evaluations.
"); document.write("
Pharmacoeconomics 34, 1161-1172 (2016)
"); document.write("
"); document.write("
"); document.write("
Mensch,\ A.*\ ; Stock,\ S.*\ ; Stollenwerk,\ B.\ ; Müller,\ D.*
"); document.write("
Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
"); document.write("
Pharmacoeconomics 33, 271-283 (2015)
"); document.write("
"); document.write("
"); document.write("
Rogowski,\ W.H.\ ; Payne,\ K.*\ ; Schnell-Inderst,\ P.*\ ; Manca,\ A.*\ ; Rochau,\ U.*\ ; Jahn,\ B.*\ ; Alagoz,\ O.*\ ; Leidl,\ R.\ ; Siebert,\ U.*
"); document.write("
Concepts of \'personalization\' in personalized medicine: Implications for economic evaluation.
"); document.write("
Pharmacoeconomics 33, 49-59 (2015)
"); document.write("
"); document.write("
"); document.write("
Schremser,\ K.\ ; Rogowski,\ W.H.\ ; Adler-Reichel,\ S.*\ ; Tufman,\ A.L.*\ ; Huber,\ R.M.\ ; Stollenwerk,\ B.
"); document.write("
Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on \EGFR\ mutation testing in advanced lung adenocarcinoma patients in Germany.
"); document.write("
Pharmacoeconomics 33, 1215-1228 (2015)
"); document.write("
"); document.write("
"); document.write("
Hatz,\ M.H.M.\ ; Schremser,\ K.\ ; Rogowski,\ W.H.
"); document.write("
Is individualized medicine more cost-effective? A systematic review.
"); document.write("
Pharmacoeconomics 32, 443-455 (2014)
"); document.write("
"); document.write("
"); document.write("
Hatz,\ M.H.M.\ ; Leidl,\ R.\ ; Yates,\ N.A.\ ; Stollenwerk,\ B.
"); document.write("
A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
"); document.write("
Pharmacoeconomics 32, 377-393 (2014)
"); document.write("
"); document.write("
"); document.write("
Heimeshoff,\ M.*\ ; Hollmeyer,\ H.*\ ; Schreyögg,\ J.\ ; Tiemann,\ O.\ ; Staab,\ D.*
"); document.write("
Cost of illness of cystic fibrosis in Germany: Results from a large cystic fibrosis centre.
"); document.write("
Pharmacoeconomics 30, 763-777 (2012)
"); document.write("
"); document.write("
"); document.write("
Menn,\ P.\ ; Leidl,\ R.\ ; Holle,\ R.
"); document.write("
A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.
"); document.write("
Pharmacoeconomics 30, 825-840 (2012)
"); document.write("
"); document.write("
"); document.write("
Blankart,\ C.R.B.\ ; Stargardt,\ T.\ ; Schreyögg,\ J.
"); document.write("
Availability of and access to orphan drugs: An international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
"); document.write("
Pharmacoeconomics 29, 63-82 (2011)
"); document.write("
"); document.write("
"); document.write("
Leidl,\ R.\ ; Reitmeir,\ P.
"); document.write("
A value set for the EQ-5D based on experienced health states: Development and testing for the German population.
"); document.write("
Pharmacoeconomics 29, 521-534 (2011)
"); document.write("
"); document.write("
"); document.write("
Menn,\ P.\ ; Holle,\ R.
"); document.write("
Comparing three software tools for implementing markov models for health economic evaluations.
"); document.write("
Pharmacoeconomics 27, 745-753 (2009)
"); document.write("
"); document.write("
"); document.write("
Kreck,\ S.*\ ; Klaus,\ J.*\ ; Leidl,\ R.\ ; von Tirpitz,\ C.*\ ; Konnopka,\ A.*\ ; Matschinger,\ H.*\ ; König,\ H.H.*
"); document.write("
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: Cost-utility analysis using a Markov model.
"); document.write("
Pharmacoeconomics 26, 311-328 (2008)
"); document.write("
"); document.write("
"); document.write("
Bos,\ J.M.*\ ; Rümke,\ H.C.*\ ; Welte,\ R.\ ; Spanjaard,\ L.*\ ; van Alphen,\ L.*\ ; Postma,\ M.J.*
"); document.write("
Combination vaccine against invasive meningococcal B and pneumococcal infections: Potential epidemiological and economic impact in The Netherlands.
"); document.write("
Pharmacoeconomics 24, 141-153 (2006)
"); document.write("
"); document.write("
"); document.write("
Stark,\ R.G.\ ; König,\ H.-H.*\ ; Leidl,\ R.
"); document.write("
Costs of inflammatory bowel disease in Germany.
"); document.write("
Pharmacoeconomics 24, 797-814 (2006)
"); document.write("
"); document.write("
"); document.write("
Welte,\ R.\ ; Trotter,\ C.*\ ; Edmunds,\ W.*\ ; Postma,\ M.J.*\ ; Beutels,\ P.*
"); document.write("
The Role of Economic Evaluation in Vaccine Decision Making.
"); document.write("
Pharmacoeconomics 23, 855-874 (2005)
"); document.write("
"); document.write("
"); document.write("
Welte,\ R.\ ; Feenstra,\ T.*\ ; Jager,\ H.*\ ; Leidl,\ R.
"); document.write("
A decision chart for assessing and improving the transferability of economic evaluation results between countries.
"); document.write("
Pharmacoeconomics 22, 857-876 (2004)
"); document.write("
");